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Ser935 phosphorylationThe leucine-rich repeat kinase 2 mutation G2019S in the kinase-domain is the most common genetic cause of
Parkinson's disease. To investigate the impact of the G2019Smutation onmotor activity in vivo, a longitudinal phe-
notyping approach was developed in knock-in (KI) mice bearing this kinase-enhancing mutation. Two cohorts of
G2019S KI mice and wild-type littermates (WT) were subjected to behavioral tests, speciﬁc for akinesia, bradyki-
nesia and overall gait ability, at different ages (3, 6, 10, 15 and 19 months). The motor performance of G2019S KI
mice remained stable up to the age of 19 months and did not show the typical age-related decline in immobility
time and stepping activity of WT. Several lines of evidence suggest that enhanced LRRK2 kinase activity is the
main contributor to the observed hyperkinetic phenotype of G2019S KI mice: i) KI mice carrying a LRRK2
kinase-deadmutation (D1994S KD) showed a similar progressivemotor decline asWT; ii) two LRRK2 kinase inhib-
itors, H-1152 and Nov-LRRK2-11, acutely reversed the hyperkinetic phenotype of G2019S KI mice, while being in-
effective inWT or D1994S KD animals. LRRK2 target engagement in vivo was further substantiated by reduction of
LRRK2 phosphorylation at Ser935 in the striatum and cortex at efﬁcacious doses of Nov-LRRK2-11, and in the stri-
atumat efﬁcacious doses ofH-1152. In summary, expression of theG2019Smutation in themouse LRRK2 gene con-
fers a hyperkinetic phenotype that is resistant to age-relatedmotor decline, likely via enhancement of LRRK2 kinase
activity. This study provides an in vivo model to investigate the effects of LRRK2 inhibitors on motor function.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene (PARK8,
OMIM 609007) are associated to late-onset, autosomal dominant
Parkinson's disease (PD), and account for up to 13% of familial and 1–2%
of sporadic PD cases (Paisan-Ruiz et al., 2004; Zimprich et al., 2004).
LRRK2-associated PD is clinically similar to idiopathic forms, and is char-
acterized by the degeneration of substantia nigra dopaminergic neurons
usually with α-synuclein and ubiquitin positive Lewy body formation
(Healy et al., 2008). Furthermore, variations in LRRK2 have been linked
to other diseases, leprosy (Zhang et al., 2009), cancer (Hassin-Baer et al.,
2009) and possibly inﬂammatory bowel disease (Barrett et al., 2008) al-
though the latter is controversial (Kumar et al., 2013). LRRK2 is a largeA, dopamine; KI, knock-in; KD,
rkinson's disease; ROC, Ras Of
nces, Section of Pharmacology,
1 Ferrara, Italy. Fax: +39 0532
ect.com).
. This is an open access article undermultifunctional protein, essentially consisting of a GTPase/ROC (Ras Of
Complex) along with its COR (C-terminal Of ROC) domain, a kinase
domain, and a number of protein-protein interaction domains including
ankyrin and leucine-rich repeat motifs at the N-terminus, and WD40 re-
peats at the C-terminus (Cookson, 2010; Marin, 2006). The pathogenic
mutations of LRRK2 are clustered among the central tridomain region
that forms the catalytic core of the protein (Cookson, 2010; Mata et al.,
2006). The substitution of a glutamate with a serine in position 2019
(G2019S) is themost common familial mutation, and has attracted great-
er interest because it enhances LRRK2 kinase activity in vitro (Greggio
et al., 2006; Jaleel et al., 2007; West et al., 2005) and in vivo (Sheng
et al., 2012), resulting in neuronal toxicity in vitro (Iaccarino et al.,
2007; Smith et al., 2005). Interestingly, non-selective LRRK2 inhibitors
were shown to protect against G2019S LRRK2-induced neurodegenera-
tion in vivo (Liu et al., 2011), indicating that inhibition of LRRK2 activity
may represent a valuable target in a PD therapeutic perspective. Accord-
ingly, these ﬁndings have provided the rationale for developing selective
LRRK2 kinase inhibitors (Choi et al., 2012; Estrada et al., 2012, 2014;
Herzig et al., 2011; Nichols et al., 2009; Troxler et al., 2013) for their
potential antiparkinsonian activity (Lee et al., 2010; Liu et al., 2011).
Quite disappointingly, however, the attempts to reproduce
parkinsonian-like motor deﬁcits in rodents expressing G2019S LRRK2the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Lachenmayer, 2011), and, as a consequence, a reliable rodent model
for testingmotor effects of LRRK2 inhibitors in vivo is currently unavail-
able. Indeed, mice overexpressing human or murine G2019S using bac-
terial artiﬁcial chromosome (BAC) transgenesis did not show any
impairment of motor performance, and insteadwere found hyperactive
in some tests (Li et al., 2010; Melrose et al., 2010). Consistently, mice
overexpressing human G2019S LRRK2 under the Thy1 (Herzig et al.,
2012), CaMKII (TetO) (Lin et al., 2009) or CMV/PDGF (Ramonet et al.,
2011) artiﬁcial promoters showed, if any, improvements inmotor activ-
ity. Finally, rats temporarily (but not constitutively) overexpressing
G2019S, show increased exploratory behavior in the open ﬁeld at
20 months but not at earlier ages (Zhou et al., 2011). Although it is pos-
sible that the degree of G2019S transgene overexpression in midbrain
dopamine (DA) neurons, which is promoter-dependent, drives the
motor phenotype (Chen et al., 2012), the data so far accumulated in ro-
dents overexpressing G2019S LRRK2 suggest, at most, that low expres-
sion levels of G2019S are not detrimental for motor function. Actually,
the consistent observations of test-dependent, mild improvements of
motor activity across these studies call for a more in-depth analysis of
the impact of G2019S LRRK2 on motor function, using a longitudinal
phenotyping strategy and behavioral testsmore speciﬁc formotor func-
tion. In fact, most studies are limited to the use of the open ﬁeld test,
wheremotor performance can be inﬂuenced by affective states. In addi-
tion, studies in G2019S overexpressing animals may be criticized for ar-
tiﬁcially enhancing LRRK2 levels in areas where LRRK2 physiological
expression is low (e.g. the substantia nigra pars compacta), and for
overlooking the interference between LRRK2 mutants and native en-
dogenous LRRK2, still expressed.
For these reasons, in the present study we enrolled two cohorts of
G2019S knock-in (KI) mice and wild-type littermates (WT), and ana-
lyzed their motor activity from the age of 3 to 19 months, using a set
of complementary behavioral tests, speciﬁc for akinesia, bradykinesia
and overall gait ability (the bar, drag and rotarod tests; Marti et al.,
2005; Viaro et al., 2008). Our study revealed that G2019S KI mice had
enhanced motor activity compared to WT already at 3 months of age,
and throughout aging. To conﬁrm that enhanced kinase activity
accounts for this phenotype, we performed a parallel longitudinal
study in mice carrying a LRRK2 mutation (D1994S) that impairs kinase
activity (kinase-dead, D1994S KD), in comparison with their own WT.
In addition, we tested the ability of small molecular-weight ATP analo-
gous LRRK2 kinase inhibitors to reverse the hyperkinetic phenotype of
G2019S KI mice. In vivo LRRK2 targeting of kinase inhibitors was
conﬁrmed by measuring LRRK2 phosphorylation at Ser935 (Dzamko
et al., 2010).Materials and methods
Animals
Male homozygous LRRK2 G2019S KI and KD mice backcrossed on a
C57Bl/6J background were obtained from Novartis Institutes for
BioMedical Research, Novartis Pharma AG (Basel, Switzerland). Male
non-transgenic wild-type (WT) mice were littermates obtained from
the respective heterozygous breeding. The mice used in our study
were generated at Novartis laboratories, andwere previously character-
ized from several biochemical and neuropathological standpoints, al-
though motor analysis was limited to the open ﬁeld in 5-month old
animals (Herzig et al., 2011).
Mice employed in the study were kept under regular lighting condi-
tions (12 h light/dark cycle) and given food andwater ad libitum. Exper-
imental procedures involving the use of animals were approved by the
Ethical Committee of the University of Ferrara and the Italian Ministry
of Health (licenses 171/2010-B and 318/2013-B). Adequate measures
were taken to minimize animal pain and discomfort.Experimental design
The longitudinal study was conducted on two cohorts of G2019S KI
(n = 19) and their WT (n = 12) littermates. Mice were received from
Novartis at the age of about 2 months, and accommodated in the vivar-
ium of theUniversity of Ferrara.Micewere subjected tomotor tests at 3,
6, 10, 15 and 19 months. D1994S KD and their WT mice (n= 10 each)
were tested at 3, 6, 10 and 15 months. Separate, age-matched cohorts of
3, 10, 14 and 18-month-old WT and G2019S KI mice (6–8 mice per
group) were enrolled in transversal behavioral studies, to parallel the
results of the longitudinal study. Finally, other cohorts of mice (n = 10
each genotype) were used for pharmacological studies with LRRK2
kinase inhibitors at 6, 12 and 15 months (G2019S KI), or 12 months
(D1994S KD).
Behavioral tests
Motor activity was evaluated by means of three behavioral tests spe-
ciﬁc for different motor abilities, as previously described (Marti et al.,
2005, 2007; Viaro et al., 2008): the bar, drag and rotarod test. Animals
were trained for 4 days to the speciﬁc motor tasks in order to obtain a re-
producible motor response, and then tested at the 5th day, both in the
phenotyping and pharmacological studies. For pharmacological studies,
the test sequence (bar, drag and rotarod) was repeated before (T0) and
at different time-points (depending on the experiment) after drug injec-
tion. Experimenters were blinded to genotype and treatments.
Bar test
Originally developed to quantify morphine-induced catalepsy
(Kuschinsky and Hornykiewicz, 1972), this test measures the ability of
the animal to respond to an externally imposed static posture. Also
known as the catalepsy test (for a review see (Sanberg et al., 1988)), it
can also be used to quantify akinesia (i.e. time to initiate a movement)
also under conditions that are not characterized by increased muscle
tone (i.e. rigidity) as in the cataleptic/catatonic state. Mice were gently
placed on a table and forepaws were placed alternatively on blocks
of increasing heights (1.5, 3 and 6 cm). The time (in seconds) that
each paw spent on the block (i.e. the immobility time) was recorded
(cut-off time of 20 s). Performance was expressed as total time spent
on the different blocks.
Drag test
Modiﬁcation of the ‘wheelbarrow test’ (Schallert et al., 1979), this
test measures the ability of the animal to balance its body posture
with the forelimbs in response to an externally imposed dynamic stim-
ulus (backward dragging) (Marti et al., 2005). It gives information re-
garding the time to initiate and execute (bradykinesia) a movement.
Animals were gently lifted from the tail leaving the forepaws on the
table, and then dragged backwards at a constant speed (about 20 cm/s)
for a ﬁxed distance (100 cm). The number of steps made by each paw
was recorded. Five to seven determinations were collected for each
animal.
Rotarod test
The ﬁxed-speed rotarod test (Rozas et al., 1997) measures different
motor parameters such as motor coordination, gait ability, balance,
muscle tone and motivation to run. Mice were tested over a wide
range of increasing speeds (0–55 rpm; 5 rpm steps, increased every
180 s) on a rotating rod (diameter of the cylinder 8 cm) (Marti et al.,
2004; Viaro et al., 2008) and the total time spent on the rod was
recorded.
64 F. Longo et al. / Neurobiology of Disease 71 (2014) 62–73Spontaneous motor activity
The open ﬁeld test was used to measure spontaneous locomotor
activity in 15-month-old mice. The ANY-maze video tracking system
was used (Ugo Basile, application version 4.52c Beta) as previously
described (Rizzi et al., 2008). Brieﬂy, mice were placed in a square plas-
tic cage (40 × 40 cm), one mouse per cage, and ambulatory behavior
(horizontal activity) was monitored for 60 min with a camera. Four
mice were monitored simultaneously each experiment. Total distance
traveled (m) and immobility time (sec) were recorded.
LRRK2 kinase inhibitor administration
Twelve-month-old mice were administrated i.p. with the LRRK2
kinase inhibitor H-1152 (Nichols et al., 2009; Sasaki et al., 2002;
Tamura et al., 2005) at two different dose levels (0.1 and 1 mg/kg), or
with the LRRK2 kinase inhibitor Nov-LRRK2-11 (Herzig et al., 2011;
Troxler et al., 2013), at two different dose levels (1 and 10 mg/kg) for
the indicated time. H-1152was dissolved in 0.9% saline solutionwhere-
as Nov-LRRK2-11 in 3% DMSO/3% Tween 80.
Cell culture and treatments
NIH3T3 cells were cultured in Dulbecco's Modiﬁed Eagle's medium
(Life technologies) supplemented with 10% fetal bovine serum (Life
technologies), penicillin and streptomycin (Life technologies) and
maintained at 37 °C in a 5% CO2 controlled atmosphere. H-1152
(SiChem) and Nov-LRRK2-11 (Novartis) were dissolved in 0.9% saline
solution and in 3% DMSO/3% Tween 80/0.9% saline, respectively. Inhibi-
tors were used at the indicated concentrations, and equivalent volumes
of saline solution were used as control. Inhibitors were added to the
culture medium for 90 min before cell lysis.
Cells and tissue lysis
NIH3T3 cells, aswell as striatum and cortex obtained from brain dis-
section were homogenized and solubilized in lysis buffer (20 mM Tris–
HCl pH 7.5, 150mMNaCl, 1 mM EDTA, 2.5 mM sodium pyrophosphate,
1 mM β-glycerophosphate, 1 mM Na3VO4) supplemented with 1% Tri-
ton X-100 (Sigma Aldrich) and protease inhibitor cocktail (Roche),
then cleared at 14,000 g at 4 °C for 30 min. Protein concentrations
were determined using the bicinchoninic acid assay (BCA) as
manufacturer's instructions (Thermo Scientiﬁc).
Western blotting
Proteins were separated by electrophoresis into pre-casted 4–
20% SDS-PAGE gels (Biorad) and subsequently transferred onto
Immobilon-P membrane (Millipore). Membranes were ﬁrst incu-
bated 1 h at RT with rabbit anti-LRRK2 phospho Ser935 (1:300,
Abcam, RabMAbs cat#ab133450), rabbit anti-LRRK2 UDD3 (1:1000,
Abcam, RabMAbs cat# ab133518) and mouse anti-GADPH (1:4000,
Millipore), then with HRP-conjugated secondary antibodies (Sigma)
for 1 h at room temperature and then incubated with enhanced chemi-
luminescent (ECL) western blot substrate (Thermo Scientiﬁc).
In vivo PK study
In order to gain insights on the brain penetration of Nov-LRRK2-11, a
screening cassette approach was used, as previously described (Troxler
et al., 2013). Adultmale C57Bl/6mice (20–30 g, Iffa-Credo, France)were
orally administered (by gavage) with Nov-LRRK2-11 (suspended in
carboxymethylcellulose 0.5 % w/v in water with Tween 80 at 0.5% v/v)
at a dose of 3 mg/kg p.o.. Volume of oral administration was 10 mL/kg
body weight.After drug cassette administration, blood (~50 μL in EDTA) was col-
lected at different time points (15 min, 30 min, 1, 2, 4, 8 and 24 h post-
dose, n = 3 mice per time-point,) either by puncture of the sublingual
vein (~70 μL/mouse, under light anesthesia) or by puncture from the
vena cava at sacriﬁce (~300 μL/mouse). Moreover, at sacriﬁce (at 15
min, 1, 4, and 24 h post-dose), brains were removed, weighted and
immediately frozen on dry ice. Blood and brain samples were stored
at −20 °C until analysis. Samples were analyzed for Nov-LRRK2-11
content with LC–MS/MS methodologies.
Data presentation and statistical analysis
Data are expressed as absolute values and are mean ± SEM (stan-
dard error of themean) of nmice. To assess the signiﬁcance of behavior-
al changes over the 19-month longitudinal study (Figs. 1–2) a linear
mixed-model repeated measures analysis using the REPEATED state-
mentwas used, followed by the Bonferroni test (PROCMIXED, SAS, ver-
sion 9.2, SAS Institute Inc, Cary, NC, USA). Genotype was set as discrete
variable, weight as continuous variable. This allowed to verify whether
changes in weight could account for changes in behavioral perfor-
mances. Statistical analysis of drug effect was performed by one-way
repeated measure (RM) analysis of variance (ANOVA) followed by the
Newman–Keuls test for multiple comparisons, or by two-way ANOVA
followed by Bonferroni test for multiple comparisons (Table 1). Instead,
two groups of data were compared with Student's t-test, two tailed
for unpaired data. p-values b 0.05 were considered to be statistically
signiﬁcant.
Results
G2019S KI mice showed greater motor performance than WT mice
To investigate whether the kinase-enhancing G2019S point-
mutation in murine LRRK2 affects motor performance, two cohorts of
G2019S KI mice (n = 19) and age-matched WT littermates (WT;
n = 12) were enrolled in a longitudinal study in which motor activity
was measured using the bar, drag and rotarod tests from 3 through
19 months of age (Fig. 1).
G2019S KImice had throughout the study a lower body weight than
WT (Table 1). The difference was 14% on average.
In the bar test (Fig. 1A), a signiﬁcant effect of genotype (F1,75 =
45.52, p b 0.0001), time (F4,75 = 4.47, p = 0.0027) and their interac-
tion (F4,75 = 6.40, p = 0.0002) was found. The inﬂuence of weight
was found not to be signiﬁcant (F1,75 = 3.50, p = 0.07). Immobility
time of G2019S KI mice in the bar test (8.5 ± 2.1 s) was not different
from that of WT (12.4 ± 2.9 s) at 3 months (Fig. 1A). Immobility
time increased along with aging in WT mice reaching a maximum of
33.7 ± 2.3 s at 19 months. Conversely, G2019S KI mice did not become
akinetic with aging, showing similar performances across the study.
The difference between genotypes was evident starting at 6 months
(~2-fold), and attained stable values (~3-fold) from 10 months
onward. In the drag test (Fig. 1B), a signiﬁcant effect of genotype
(F1,75 = 91.11, p b 0.0001), time (F4,75 = 26.78, p = 0.0027) and
their interaction (F4,75 = 6.11, p = 0.0003) was found. As in the
bar test, no signiﬁcant inﬂuence of weight was observed (F1,75 = 1.54,
p = 0.22). G2019S KI mice showed a signiﬁcant 23% greater stepping
activity than WT at 3 months (21.7 ± 1.1 vs 17.7 ± 0.7 steps, respec-
tively). This difference became 2–3-fold larger in older animals, since
stepping activity of WT mice progressively worsened over time,
reaching 3.4 ± 0.3 steps at 19 months, whereas that of G2019S KI
mice remained stable up to 15 months, showing a signiﬁcant decline
only at 19 months (10.7 ± 1.1 steps). Different from the bar and drag
test, no signiﬁcant effect of genotype was found in the rotarod test
(F1,75 = 0.01, p = 0.92), but a signiﬁcant effect of time (F4,75 = 8.24,
p b 0.0001) and genotype × time interaction (F4,75 = 3.81, p =
0.0071). Also in this test, the inﬂuence of weight was not signiﬁcant
Fig. 1. LRRK2 G2019S knock-in (G2019S KI)mice showed greatermotor performances thanwild-type littermates (WT).Motor performancewas evaluated in two cohorts ofmice follow-
ing a longitudinal phenotyping approach. Micewere subjected to a set of tests, namely the bar (A), drag (B) and rotarod (C) tests, from3 up to 19 months of age. In addition, an openﬁeld
testwasperformed in15-month old animals (D–E).Motor activitywas expressed as immobility time (sec;A,D), number of steps (B), time on rod (sec; C), and total distance traveled (m; E).
Data aremeans± SEM of 9–10 (3–15 months) or 6 (19 months)mice per group, andwere analyzed using one-way RMANOVA followed by theNewman–Keuls test formultiple compar-
isons. Differences between genotypes at the single time-point levels were evaluated using the Student t-test, two tailed for unpaired data. *P b 0.05, **P b 0.01 different from 3-month-old
mice of the same genotype. °P b 0.05,°°P b 0.01 different from age-matched littermates.
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WT mice was observed along with aging (10 and 19 months), whereas
that of G2019S KI mice remained stable throughout the study (Fig. 1C).
The open ﬁeld test was performed in 15-month-old animals. G2019S KI
mice showed 42% shorter immobility time (t = 2.53, df = 8, p = 0.036;
Fig. 1D) and 43% longer distance traveled (t = 4.15, df = 8, p = 0.003;
Fig. 1E) compared to WT.
To conﬁrm the hyperkinetic phenotype of G2019S KI mice, the bar,
drag, rotarod and open ﬁeld tests were repeated in age-matched sepa-
rate cohorts of 3, 10, 14 and 18-month-oldmice, not involved in the lon-
gitudinal study (Fig. S1). These experiments substantially conﬁrmed
that G2019S KI mice were hyperactive, with signiﬁcant differences
with WT emerging already at 3 months in the bar and drag tests, and
at 10 months in the open ﬁeld. As in the longitudinal study, noFig. 2.Mice carrying a LRRK2 mutation (D1994S) that silences kinase activity (kinase-dead; D1
mance was evaluated in two cohorts of mice following a longitudinal phenotyping approach.
starting at 3 months up to 19 months of age. In addition, an open ﬁeld test was performed in
D), number of steps (B), time on rod (sec; C), and total distance traveled (m; E). Data are mea
by the Newman–Keuls test for multiple comparisons. Differences between genotypes at the s
data. **P b 0.01 different from 3-month-old mice of the same genotype.differences in rotarod performance were observed between age-
matched cohorts of WT and G2019S KI mice.
D1994S KD mice behaved similar to WT in motor tests
Since experiments in G2019S KI mice suggested that enhancement
of kinase activity is associated with greater motor performance, we in-
vestigated if kinase activity silencingmutationmight cause a differential
effect. To this purpose, we used mice bearing the kinase-inactivating
point mutation D1994S (D1994S KD) and age-matchedWT littermates.
No difference in weight was observed between D1994S KD andWT
mice throughout the study (Table 1). Statistical analysis of bar test
values revealed no signiﬁcant effect of genotype (F1,67 = 0.1, p =
0.74), a signiﬁcant effect of time (F3,67 = 31.23, p b 0.001) but not a994S KD) showed similar motor phenotype of wild-type littermates (WT). Motor perfor-
Mice were subjected to a set of tests, namely the bar (A), drag (B) and rotarod (C) tests,
15-month-old animals (D–E). Motor activity was expressed as immobility time (sec; A,
ns ± SEM of 10 mice per group, and were analyzed using one-way RM ANOVA followed
ingle time-point levels were evaluated using the Student t-test, two-tailed for unpaired
Table 1
G2019S LRRK2 knock-in (KI)miceweighed less thanwild-type littermates (WT) throughout the study. No differencewas observed betweenD1994S LRRK2 kinase-dead (D1994S KD) and
respective WT littermates. Data are expressed in grams and are means ± SEM of the number of mice indicated in parentheses.
*P b 0.05, **P b 0.01 different fromWT (2-way ANOVA followed by the Bonferroni post hoc test).
Age (months)
Genotype 3 6 9 15 19
G2019S KI (g) 23.8 ± 0.9** (11) 27.5 ± 0.4** (11) 30.4 ± 0.4** (11) 30.9 ± 0.4** (11) 31.8 ± 0.4* (6)
WT (g) 28.8 ± 0.8 (9) 31.5 ± 0.8 (9) 34.7 ± 0.8 (9) 35.3 ± 1.2 (9) 36.2 ± 1.4 (6)
D1994S KD (g) 25.6 ± 0.4 (10) nt 32.0 ± 0.6 (10) 33.1 ± 0.7 (10) nt
WT (g) 26.0 ± 0.4 (9) nt 33.4 ± 0.7 (9) 34.6 ± 0.7 (9) nt
nt = not tested.
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drag test, a signiﬁcant effect of time (F3,67 = 42.21, p b 0.001), but not
of genotype (F1,67 = 0.48, p = 0.49) or genotype × time interaction
(F3,67= 0.56, p= 0.64)was found. Only in the rotarod test, a signiﬁcant
effect of genotype (F1,67 = 16.11, p = 0.0002) and time (F3,67 = 10.79,
p b 0.0001) but not their interaction (F3,67= 0.63, p= 0.62)was found.
Overall, basal activity in the bar (Fig. 2A), drag (Fig. 2B) and rotarod
(Fig. 2C) test was similar between D1994S KD mice and their WT at
any age analyzed. As expected,WT but aswell D1994S KDmice showed
a signiﬁcant worsening of motor activity in the bar (increase of immo-
bility time) and drag (reduction of stepping activity) tests at 10 and
15 months. Transient improvement of rotarod performance was ob-
served in WT and D1994S KD mice at 10 months. Consistently, no
difference in exploratory behavior was observed between genotypes
in the open ﬁeld at 15 months (immobility time t = 0.21, df = 7,
p = 0.84; distance traveled t = 0.03, df = 7, p = 0.97) Figs. 2D–E).
WT mice obtained from both colonies (G2019S KI and D1994S KD)
showed substantially similar performances throughout the study (Tab.
S1), with the exception of rotarod performance which was signiﬁcantly
lower at 3 and 6 months in WT littermates of G2019S KI mice.
The LRRK2 inhibitor H-1152 reversed the motor phenotype of G2019S KI
mice
Since results obtained with G2019S KI and D1994S KDmice suggest
that the greater motor performance associated with the G2019S muta-
tion is dependent on kinase activity, we next asked whether LRRK2
kinase inhibitors acutely administered to G2019S KImicewere effective
at returning the hyperkinetic phenotypes to WT levels. We ﬁrst used
H-1152, a ROCK (Rho kinase) inhibitor (Nichols et al., 2009; Sasaki
et al., 2002; Tamura et al., 2005) which has been previously shown
to display high potency against LRRK2 (Gilsbach et al., 2012; Nichols
et al., 2009). We initially conﬁrmed that H-1152 was effective at
inhibiting endogenous LRRK2 in NIH3T3 mouse ﬁbroblasts, using de-Fig. 3. The LRRK2 kinase inhibitor H-1152 attenuated endogenous LRRK2 phosphorylation a
concentrations of H-1152 (0.03–10 μM) for 90 min (B). Data are means ± SEM of 2 experimenphosphorylation of Ser935 as readout of LRRK2 kinase activity, as previ-
ously described (Dzamko et al., 2010). As shown in Fig. 3, H-1152
induced Ser935 de-phosphorylation in a concentration-dependent
manner, with apparent IC50 of 170 nM.
We next assessed H-1152 in vivo. In 6-month old mice, H-1152
was ineffective at 0.1 mg/kg, but increased immobility time
(treatment F2,21 = 5.37, p = 0.013; time F1,21 = 0.72, p = 0.41;
time × treatment interaction F2,21 = 10.87, p b 0.0001; Fig. S2A)
and reduced stepping activity (treatment F2,21 = 4.69, p = 0.021;
time F1,21 = 22.58, p b 0.0001; time × treatment interaction F2,21 =
5.93, p b 0.009; Fig. S2B) of G2019S KI mice to the levels of WT mice at
1 mg/kg. The same dose of H-1152 did not affect rotarod performance
(treatment F2,21 = 0.06, p = 0.94; time F1,21 = 1.79, p = 0.19; time ×
treatment interaction F2,21 = 0.02, p = 0.98; Fig. S2C). The time-course
of the response to H-1152 (1 mg/kg) was next studied in 12-month
old mice (Fig. 4). Saline-treatedWT and G2019S KI mice showed stable
responses in thebar (Fig. 4A) and drag (Fig. 4B) tests across the 24-h ob-
servation period. Administration of H-1152 induced a rapid (maximal
within 30 min) and prolonged (up to 6 h) increase of immobility time
(treatment F1,8 = 59.32, p b 0.0001; time F5,8 = 14.25, p b 0.0001;
time× treatment interaction F5,40=14.17, p b 0.0001; Fig. 4A) and re-
duction of stepping activity (treatment F1,8 = 14.64; p = 0.005;
time F5,8 = 14.12, p b 0.0001; time × treatment interaction F5,40 =
13.61, p b 0.0001; Fig. 4B) in G2019S KI mice, being ineffective in WT
mice (bar test: treatment F1,8 = 0.39, p = 0.84; time F5,40 = 2.77,
p = 0.03; time × treatment interaction F5,40 = 0.92, p = 0.47; drag
test: treatment F1,8 = 0.76, p =0.41; time F5,40 = 1.57, p = 0.19;
time × treatment interaction F5,40 =1.94, p= 0.11 Fig. 4A). No residual
effect of H-1152was detected 24 h after administration. Rotarod perfor-
mance was not signiﬁcantly affected by H-1152 (G2019S KI: treatment
F1,8 = 0.21, p = 0.65; time F5,40 =6.27, p b 0.0001; time × treatment
interaction F5,40 = 0.81, p = 0.54; WT: treatment F1,8 = 2.94, p =
0.12; time F5,40 = 10.85, p b 0.0001; time × treatment interaction
F5,40 = 0.65, p= 0.64; Fig. S3). Indeed, performances worsened withint Ser935 in cells. Blots from lysates of NIH3T3 cells (A) exposed to vehicle or increasing
ts performed in duplicate.
Fig. 4. Time-course of themotor effects of the LRRK2 kinase inhibitor H-1152 in 12-month-old G2019S KImice and wild-type littermates (WT). H-1152 (1 mg/kg; i.p.) or saline were ad-
ministered to 12-month-oldmice, andmotor activity assessed using the bar (A) and drag (B) tests, before (time 0; basal values) and after (30, 90, 180, 360min, 24 h) drug administration.
Data are means ± SEM of 6 mice per group, and were analyzed using one-way RM ANOVA followed by the Newman–Keuls test for multiple comparisons. *P b 0.05, **P b 0.01 different
from basal values.
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both genotypes treated with saline or H-1152. Motor tests were re-
peated in 15-month old mice with substantially similar results
(Fig. S4), although H-1152 (1 mg/kg) also mildly and transiently im-
paired rotarod performance in G2019S KI mice. To account for a cer-
tain compound speciﬁcity of LRRK2 activity inhibition we also
treated D1994S KD mice and their wild-type controls (Figs. 5A-C).
H-1152 (1 mg/kg) treatment did not affectmotor activity in any geno-
types (bar test: genotype F1,8 =1.03, p = 0.34; time F4,32 = 0.34, p =
0.84; time× treatment interaction F4,32= 0.53, p= 0.71; drag test: ge-
notype F1,8 = 0.25, p =0.63; time F4,32 = 2.28, p = 0.08; time ×
treatment interaction F4,32 =0.34, p = 0.85; rotarod test: genotype
F1,8 = 2.64, p = 0.14; time F4,32 = 3.98, p = 0.01; time × treatment
interaction F4,32 = 0.79, p =0.53), consistent with the lack of motor
abnormalities in these animals.
Finally, we evaluated in vivo on-target engagement of H-1152 by
measuring LRRK2 phosphorylation at Ser935 in ex vivo samples of the
striatum and cerebral cortex obtained from 12-month old G2019S KI
(Figs. 6A-B) andWT (Figs. 6C-D)mice. A decrease of LRRK2 phosphory-
lation was observed in striatum (p = 0.015, t = 4.05, df = 4), but
not cerebral cortex (p= 0.095, t= 0.98, df=4), at 20min after admin-
istration of 1 mg/kg H-1152 but not later time-points (i.e. 90
and 360 min; Figs. S5A-B). Contrary to G2019S KI mice, no effect of
H-1152 on LRRK2 phosphorylation was detected in striatum (p = 0.30,
t = 1.11, df = 7) or cerebral cortex (p = 0.31, t = 1.08, df = 7) at
20 min after administration in WT mice (Figs. 6B-D)Fig. 5. The LRRK2 kinase inhibitor H-1152 did not affectmotor activity inmice carrying a LRRK2
the motor effects of H-1152 (1 mg/kg, i.p.) in 12-month-old D1994S KDmice and wild-type lit
basal values) and after (30, 120, 360min, 24 h) drug administration. Data aremeans± SEM of 6
Keuls test for multiple comparisons.Nov-LRRK2-11 conﬁrmed that the hyperactivity of G2019S KI mice is
kinase-dependent
To conﬁrm that the results obtained with H-1152 are due to LRRK2
inhibition and not other off-target kinases, we employed a second
smallmolecule ATP analog inhibitor, Nov-LRRK2-11,which has been re-
cently shown to be brain penetrant and reasonably selective (Troxler
et al., 2013). We ﬁrst tested Nov-LRRK2-11 in vitro for its ability to
inhibit LRRK2 Ser935 phosphorylation. Nov-LRRK2-11 resulted in
being very potent at reducing LRRK2 phosphorylation in NIH3T3 cells,
with IC50 of 0.38 nM (Fig. 7). Next, we assessed the compound in vivo
(Fig. 8). Nov-LRRK2-11 (1 and 10 mg/kg, i.p.) did not induce any
obvious behavioral change on immobility time and step number in
WT mice (bar test: treatment F2,13 = 39.83, p b 0.001; time F4,52 =
2.33, p =0.07; time × treatment interaction F8,52 = 0.75, p = 0.65;
drag test: treatment F2,13 = 1.05, p = 0.37; time F4,52 = 2.34, p =
0.07; time × treatment interaction F8,52 = 0.95, p = 0.48; Figs. 8A-B).
However, Nov-LRRK2-11 acute treatment phenocopied the motor
inhibiting effects of H-1152 in G2019S KI mice (bar test: treatment
F2,13 = 60.05, p b 0.0001; time F4,60 = 29.15, p b 0.0001; time × treat-
ment interaction F8,60 = 0.29.15, p b 0.0001; drag test: treatment
F2,15 = 12.65, p = 0.001; time F4,60= 18.51, p b 0.0001; time × treat-
ment interaction F8,60 = 15.55, p b 0.0001; Figs. 8A-B). Nov-LRRK2-11
was ineffective at 1 mg/kg, and induced a rapid (signiﬁcant at 20 min,
maximal at 75min) increase in immobility time (Fig. 8A) and reduction
of stepping activity (Fig. 8B) at 10 mg/kg. These effects were shortermutation (D1994S) that silences kinase activity (kinase dead; D1994S KD). Time-course of
termates (WT), assessed using the bar (A), drag (B) and rotarod (C) tests, before (time 0;
mice per group, andwere analyzed using one-way RMANOVA followed by the Newman–
Fig. 6. The LRRK2 kinase inhibitor H-1152 attenuated endogenous LRRK2 phosphorylation at Ser935 in striatum but not cerebral cortex of G2019S knock-in (G2019S KI) mice, being in-
effective in wild-type littermates (WT). Three 12-month-old LRRK2 G2019S KI mice (A–B) were used as untreated controls, and three G2019S KI mice were administered with H-1152
(1 mg/kg, i.p.). In parallel, ﬁveWT KImice (C–D)were used as controls, and fourWT KImicewere treatedwith the same dose of H-1152 (1 mg/kg, i.p.). LRRK2 phosphorylationwasmea-
sured ex-vivo in the striatum (A, C) and cerebral cortex (B, D), before (time 0; T0) and 20 min after H-1152 administration. Results are mean ± SEM of 3–5 mice per group, and were
analyzed using the Student t-test, two tailed for unpaired data. To minimize experimental variability, each sample was loaded in duplicate and the numbers plotted represent the
mean of the two technical replicates. *P b 0.05 different from basal values (T0).
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and immobility time only mildly elevated at 360 min after administra-
tion. Nov-LRRK2-11 caused a delayed reduction of rotarod performance
inWTmice at 1 and 10 mg/kg, the latter dose inducing a more rapid ef-
fect (rotarod test: treatment F2,13= 0.78, p= 0.47; time F4,52 = 12.96,
p b 0.0001; time × treatment interaction F8,52 = 3.52, p = 0.002;
175min; Fig. S6). In G2019S KImice, the lower dose induced a response
that was superimposable to that observed in WT, albeit more rapid in
onset (within 15 min) (rotarod test: treatment F2,20 = 0.94, p = 0.40;time F4,80 = 18.37, p b 0.0001; time × treatment interaction F8,80 =
3.29, p = 0.003). Behavioral data were in line with pharmacokinetic
data. In fact, following an oral dose of 3 mg/kg Nov-LRRK2-11, brain
and blood concentrations were maximal at 1 h, and only minimally de-
tected at 4 h; at 24 h, compound levels were below detection (Fig. S7).
To conﬁrm in vivo LRRK2 targeting, we measured LRRK2 phosphor-
ylation at Ser935 30 min after Nov-LRRK2-11 (10 mg/kg) administra-
tion in 12-month old G2019S KI and WT animals (Fig. 9). Nov-LRRK2-
11 markedly reduced LRRK2 phosphorylation in the striatum and
Fig. 7. The LRRK2 kinase inhibitor Nov-LRRK2-11 attenuated endogenous LRRK2 phosphorylation at Ser935 in cells. Blots from lysates of NIH3T3 cells (A) exposed to vehicle or increasing
concentrations of Nov-LRRK2-11 (0.03–10 nM) for 90 min (B). Data are means ± SEM of 2 experiments performed in duplicate.
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animals each; striatum p = 0.008, t = 4.78, df = 4; cortex p = 0.011,
t = 4.41, df = 4; Figs. 9A-B) as well as WT mice (by 60% and 80%, re-
spectively, n = 5 animals each, striatum p = 0.004, t = 3.95, df = 8;
cortex p = 0.044, t = 2.37, df = 8; Figs. 9C-D). Interestingly, in the
cerebral cortex but not striatum, pharmacological blockade of LRRK2
kinase activity reduced protein LRRK2 levels (Figs. 9B and D).
Finally, pSer935 LRRK2 and endogenous LRRK2 protein levels were
monitored in 12-month-old G2019S KI and KD mice in comparison
with their WT controls (Fig. S8). pSer935 LRRK2 levels in striatum and
cortex, as well as LRRK2 protein levels in striatum were similar across
genotypes. Likewise, similar levels of LRRK2 were found in the cortex
of G2019S KI and WT mice. D19994S KD levels were also in the same
range of G2019S KI mice, although lower than those found in their
littermates.
Discussion
Previous studies have attempted to replicate a parkinsonian-like
phenotype in rodents by overexpressingpathogenic G2019S LRRK2mu-
tation. These studies differ in many ways, such as the technology used
(BAC or cDNA trangenesis, viral vectors), the levels of transgene expres-
sion and its neuronal localization, the mouse strain and, not last, the
motor tests used. Nonetheless, these studies failed in showing aFig. 8. The LRRK2 kinase inhibitor Nov-LRRK2-11 reversed motor phenotype in G2019S knock
motor effects of Nov-LRRK2-11 (1 and 10 mg/kg, i.p.), in comparison with saline, in 12-mon
(B) tests, before (time 0; basal values) and after (15, 75, 165, 360 min) drug administration
ANOVA followed by the Newman–Keuls test for multiple comparisons. *P b 0.05, **P b 0.01 difdetrimental effect of G2019S on motor functions, unless high levels of
transgene expression are artiﬁcially attained in substantia nigra neurons
via the CMV/PDGF promoter, leading to 30–50% neuronal loss (Chen
et al., 2012). Consistent with this view, no motor change was observed
in another study on these mice (although bred on a different back-
ground), where a lower level of transgene expression in DA neurons
and, consequently, a lower degree of substantia nigra neurodegenera-
tion was achieved (18%) (Ramonet et al., 2011).
To extend previous studies, here we provide the results of the ﬁrst
longitudinal phenotyping study in G2019S KI mice, showing that
expression of mouse LRRK2 gene carrying the G2019S mutation confers
a hyperkinetic phenotype, that is resistant to age-relatedmotor decline.
The robust and long lasting hyperkinetic phenotype described was
substantially conﬁrmed by a transversal motor analysis of different
age-matched cohorts of G2019S KI and WT mice.
Two lines of evidence seem to conﬁrm that enhancement of kinase ac-
tivity, which is a consequence of the G2019S mutation (Greggio et al.,
2006; Jaleel et al., 2007;West et al., 2005), increasesmotor performance:
i) the motor function of mice carrying a kinase-silencing mutation
(D1994S) showed normal age-related motor worsening superimposable
to that of WT littermates and ii) ATP-competitive kinase inhibitors re-
versed the hyperkinetic phenotype selectively in G2019S KImice. Further
evidence that enhancement of LRRK2 kinase activity might be responsi-
ble for the observed motor phenotype in G2019S KI mice comes from-in (G2019S KI) mice being ineffective in wild-type littermates (WT). Time-course of the
th-old G2019S KI and WT mice. Motor activity was assessed using the bar (A) and drag
. Data are means ± SEM of 6–8 mice per group, and were analyzed using one-way RM
ferent from basal values.
Fig. 9. The LRRK2 kinase inhibitor Nov-LRRK2-11 attenuated endogenous LRRK2 phosphorylation at Ser935 in the striatum and cortex of both G2019S knock-in (G2019S KI) mice and
wild-type littermates (WT). Three 12-month-old G2019S KI mice (A–B) were used as untreated controls, and three G2019S KI mice were administered with Nov-LRRK2-11 (10 mg/kg,
i.p.). In parallel, ﬁveWT KI mice (C–D) were used as controls, and ﬁveWT KI mice were treated with the same dose of Nov-LRRK2-11 (10 mg/kg, i.p.). LRRK2 phosphorylation was mea-
sured ex vivo in the striatum(A, C) and cerebral cortex (B, D), before (time 0; T0) and 30min afterNov-LRRK2-11 administration. Results aremean±SEMof 3–5mice per group, andwere
analyzed using the Student t-test, two tailed for unpaired data. *P b 0.05, **P b 0.01 different from basal values (T0).
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2012). In fact, the R1441C mutation induces a milder increase of kinase
activity with respect to the G2019S mutation (West et al., 2005), or no
increase at all (Jaleel et al., 2007), and motor activity of R1441C KI mice
in the open ﬁeld and rotarod appears to be unchanged up to 24 months
of age (Tong et al., 2009).
The motor phenotype described in the present study clearly differs
from that reported in G2019S overexpressing mice, although transient
and test-related motor facilitation has been observed in those mice.
For instance, BAC mice overexpressing human G2019S LRRK2 showed
faster walking speed (and anxiety-like behavior) in the open ﬁeld(Melrose et al., 2010) whereas human G2019S overexpressors under
the Thy1 (Herzig et al., 2012) or the TetO CaMKII (Lin et al., 2009) pro-
moters showed transient improvement in rotarod performance (Herzig
et al., 2012) or increased exploratory behavior (Lin et al., 2009). In addi-
tion, rats temporarily, but not constitutively, overexpressing human
G2019S LRRK2 showed increased exploratory behavior in the open
ﬁeld at 18 months (Zhou et al., 2011).
The inﬂuence of G2019S LRRK2 on motor function was evident in
tests speciﬁc for akinesia/bradykinesia (bar and drag tests), and sponta-
neous exploratory behavior (open ﬁeld), but not in a test for exercise-
driven motor activity (rotarod). This might suggest an inﬂuence of
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involves striatal sensory–motor function (Kirik et al., 1998) whereas
the rotarod test integrates both motor and non-motor (e.g. motivation
to run) functions, and likely involves multiple brain areas (e.g. basal
ganglia and cerebellum),where LRRK2 is expressed to a different degree
(Higashi et al., 2007;Melrose et al., 2007). However, both in the bar and
drag test, the main effect of G2019S was to preserve motor function
from aging, suggesting that, more in general, G2019S mutation might
confer a phenotype which is more resistant (or less sensitive) to the
age-related motor decline.
The possibility that this hyperkinetic phenotype is associated with
changes of neurotransmitter release should be considered. Indeed,
both LRRK2 silencing (Piccoli et al., 2011) or expression of the G2019S
mutation (Migheli et al., 2013) has been reported to facilitate exocyto-
sis, consistent with the ﬁnding that toomuch or too little kinase activity
has a negative impact on vesicle trafﬁcking (Matta et al., 2012). Consis-
tently, pharmacological inhibition of LRRK2 activity impairs vesicle
endocytosis and neurotransmitter release (Cirnaru et al., 2014). More-
over, enhancement of the stimulus-induced DA release has been detect-
ed in PC12 cells expressing the G2019S mutation (Migheli et al., 2013).
Therefore, we might hypothesize that the hyperkinetic phenotype of
G2019S KI mice is due to increased DA concentration at the synaptic
cleft. Alternatively, an increased motor activity could result, even in
the absence of an elevation of DA levels, from an increased expression
of postsynaptic D1 receptors, as suggested by study in G2019S express-
ing cells (Migheli et al., 2013).
The motor phenotype of G2019S KI mice seems to be achieved
through a gain-of-function process. Indeed, silencing kinase activity
does not affect motor function. The lack of endogenous control over
motor activity by endogenous LRRK2 is further supported by the ab-
sence of a clear motor phenotype in LRRK2 knockout mice (Herzig
et al., 2011; Lin et al., 2009), although exploratory changes consistent
with anxiety-like behavior, and (transient) facilitation of rotarod perfor-
mance have also been reported in thesemice (Hinkle et al., 2012).While
our results disclose robust motor alterations in G2019S KI mice, KI mice
expressing other pathological LRRK2 mutations as well as G2019S KI
mice from other laboratories need to be assessed in these motor
tests to strengthen the involvement of LRRK2 kinase activity in this
paradigm.
Interestingly, mice carrying PD-linked mutations, such as α-
synuclein overexpressed under the Thy1 promoter (Lam et al., 2011),
or parkin and DJ-1 double knock-out mice (Hennis et al., 2014) were
found to be hyperactive and have increased striatal DA levels in their
pre-symptomatic phase, possibly indicating compensatorymechanisms
preceding nigro-striatal DA system demise. Whether the hyperactive
motor phenotype of G2019S KI mice might be considered as a result
of pre-symptomatic compensatory changes is presently under investi-
gation. To possibly support this view, asymptomatic human G2019S
carriers have higher putaminal DA turnover rate (Sossi et al., 2010).
The fact that we did not observe a reversal of motor hyperactivity into
frank hypokinesia, as in α-synuclein overexpressors (Lam et al., 2011),
up to 19 months, might indicate a longer and slower pre-symptomatic
phase in G2019S KI mice, in line with the different ages at onset of the
disease, i.e. juvenile for α-synuclein related PD, and late for G2019S re-
lated PD (Hardy et al., 2009). It will be interesting to investigate in the
future the molecular basis underlying LRRK2 G2019S-related hyperac-
tive motor performance. Indeed, the requirement of kinase activity in
LRRK2 pathogenic effects is still unclear. For instance, there is also grow-
ing evidence that the LRRK2 levels are driving the neuropathology rath-
er than the kinase activity (Herzig et al., 2011; Skibinski et al., 2014).
Nevertheless, the role of LRRK2 onmotor function and on neurotoxicity
can be two independent mechanisms.
Another important ﬁnding of the present study is the demonstration
that ATP-competitive LRRK2 kinase inhibitors reversed the motor phe-
notype in G2019S KI mice. Both H-1152 and Nov-LRRK2-11 were able
to inhibit LRRK2 kinase activity and reduce LRRK2 phosphorylation atSer935 in NIH3T3 cells. This conﬁrms previous ﬁndings that LRRK2
kinase inhibition with H-1152 abolishes binding to 14-3-3 proteins,
resulting in de-phosphorylation of LRRK2 at Ser910 and Ser935
(Dzamko et al., 2010). Based on these data, phosphorylation at Ser935
has been proposed as a readout of LRRK2 kinase activity (Dzamko
et al., 2010) although this phosphorylation is not the direct consequence
of autophosphorylation but is possibly controlled by a LRRK2-activated
kinase/phosphatase and, therefore, does not always correlate with
kinase activity (Dzamko et al., 2012).
In our hands, Nov-LRRK2-11 reversed the phenotype of G2019S KI
mice and inhibited LRRK2 phosphorylation at 10 mg/kg, conﬁrming
ex vivo pulldown experiments showing that Nov-LRRK2-11 penetrates
into the brain (Troxler et al., 2013). Behavioral data were in agreement
with PK data after 3 mg/kg oral dose, and with the apparent terminal
half-life of Nov-LRRK2-11 in blood after i.v. dosing of 1 mg/kg (0.4 h)
(Herzig et al., 2011; Troxler et al., 2013).
Interestingly, the same behavioral effect was observed at ten-fold
lower doses of H-1152, suggesting signiﬁcant brain penetration also
for H-1152, for which, however, no published pharmacokinetic are
available. Further validation of this motor reversal phenotype with
additional compounds inhibiting LRRK2 is of course desirable and
necessary.
The present study shows a clear dissociation betweenmotor chang-
es and in vivo LRRK2 phosphorylation. Indeed, Nov-LRRK2-11 inhibited
motor activity in G2019S KI mice causing only minimal effects (on
rotarod performance) in WT mice, in face of a marked inhibition of
LRRK2 phosphorylation in the striatum and cerebral cortex of both ge-
notypes. Moreover, although H-1152 consistently inhibited motor ac-
tivity and LRRK2 phosphorylation in G2019S KI but not WT mice, its
motor effects far exceeded those on LRRK2 phosphorylation.
The most parsimonious way to explain this discrepancy is that
LRRK2 de-phosphorylation at Ser935 is a marker for in vivo target
engagement of LRRK2 kinase inhibitors, but does not follow their
motor effects. Perhaps, other phosphorylation, or autophosphorylation
(Sheng et al., 2012), site(s) on LRRK2 should be monitored. In fact, we
should recall that both inhibitors target other kinases beyond LRRK2,
which may act upstream and downstream of LRRK2. For instance, PKA
has been shown to crosstalk with LRRK2 (Li et al., 2011; Muda et al.,
2014; Parisiadou et al., 2014), whereas ROCK/MLCK are involved in
actin cytoskeleton remodeling pathways, in which activity they could
crosstalk with LRRK2.
On the other hand, given the parallel (albeit temporally-dissociated)
inhibition of motor activity and striatal LRRK2 phosphorylation induced
by H-1152, we might speculate that striatal LRRK2 is a key regulator of
motor activity. In this case, if higher LRRK2 kinase activity is present in
the striatumof G2019S KImice compared toWTmice, as predicted, nor-
malization of these levels by LRRK2 kinase inhibitors might represent
the trigger of a cascade of events leading to sustained motor inhibition.
Moreover, the different patterns of LRRK2 de-phosphorylation of
Nov-LRRK2-11 and H-1152 in G2019S KI andWTmice suggest a higher
LRRK2 selectivity and/or brain exposure/free fraction of Nov-LRRK2-11.
For further conﬁrmation, additional information on earlier times-points
(b20 min) of Nov-LRRK2-11 effects as well as higher doses of H-1152
would be desirable. In addition, the ﬁnding that Nov-LRRK2-11 reduces
LRRK2 levels in the cortex but not striatum indicates different properties
of the LRRK2 system in these two areas.
Concluding remarks
The present longitudinal phenotypic study provides genetic
evidence that expression of the G2019S mutation under the endoge-
nous promoter confers mice with better motor performances and pre-
serves their age-related motor decline in tests speciﬁc for akinesia/
bradykinesia. Enhancement of LRRK2 kinase activity likely underlies
this phenotype since D1994S KD mice do not display motor abnormal-
ities, and ATP-competitive LRRK2 inhibitors reversed motor phenotype
72 F. Longo et al. / Neurobiology of Disease 71 (2014) 62–73in G2019S KI mice. This study challenges the idea that G2019S is detri-
mental formotor activity in rodents, suggesting that other factorsmight
be involved in inducing a PD-like phenotype, such alpha-synuclein (for
reviews see (Greggio et al., 2011; Taymans and Cookson, 2010) or
parkin (Smith et al., 2005). The possibility that the hyperkinetic pheno-
type of G2019S KI mice might reﬂect a pre-symptomatic stage of PD
needs also to be explored. Finally, but not less important, this study
also describes for the ﬁrst time a correlation between in vivo motor
effects of LRRK2 inhibitors and their ability to de-phosphorylate
LRRK2 at Ser935, suggesting the G2019S KI mice may represent a
valuable in vivo model to screen for LRRK2 inhibitors.
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